- Home
- GT vs NVAX Comparison
GT vs NVAX Comparison
Compare GT & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GT | NVAX |
|---|---|---|
| Founded | 1898 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Automotive Aftermarket | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.6B |
| IPO Year | 2005 | 1996 |
Fundamental Metrics
Financial Performance| Metric | GT | NVAX |
|---|---|---|
| Price | $7.11 | $10.60 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 5 | 9 |
| Target Price | $10.56 | ★ $11.33 |
| AVG Volume (30 Days) | ★ 8.0M | 4.3M |
| Earning Date | 05-11-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 309.76 |
| EPS | N/A | ★ 2.58 |
| Revenue | ★ $18,280,000,000.00 | $1,123,479,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.38 | N/A |
| P/E Ratio | ★ N/A | $3.85 |
| Revenue Growth | N/A | ★ 64.69 |
| 52 Week Low | $6.51 | $5.01 |
| 52 Week High | $12.03 | $11.85 |
Technical Indicators
Market Signals| Indicator | GT | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 24.58 | 62.16 |
| Support Level | $6.64 | $6.34 |
| Resistance Level | $7.33 | $11.85 |
| Average True Range (ATR) | 0.28 | 0.72 |
| MACD | -0.16 | 0.05 |
| Stochastic Oscillator | 4.37 | 62.35 |
Price Performance
Historical ComparisonAbout GT The Goodyear Tire & Rubber Company
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment. The company operates its business through three operating segments representing its regional tire businesses: Americas; Europe, the Middle East, and Africa (EMEA); and the Asia Pacific.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.